A detailed history of Creative Planning transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 23,233 shares of ESPR stock, worth $59,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,233
Previous 20,597 12.8%
Holding current value
$59,708
Previous $45,000 15.56%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$1.61 - $2.73 $4,243 - $7,196
2,636 Added 12.8%
23,233 $38,000
Q2 2024

Aug 15, 2024

BUY
$1.84 - $3.24 $37,898 - $66,734
20,597 New
20,597 $45,000
Q3 2023

Nov 16, 2023

BUY
$0.96 - $1.79 $96 - $179
100 New
100 $0
Q1 2020

May 05, 2020

SELL
$27.44 - $73.84 $216,117 - $581,563
-7,876 Closed
0 $0
Q3 2019

Nov 01, 2019

SELL
$34.47 - $47.53 $8,100 - $11,169
-235 Reduced 2.9%
7,876 $289,000
Q2 2019

Jul 26, 2019

SELL
$40.1 - $52.33 $781,669 - $1.02 Million
-19,493 Reduced 70.62%
8,111 $377,000
Q1 2019

Apr 24, 2019

BUY
$40.11 - $53.57 $792,373 - $1.06 Million
19,755 Added 251.69%
27,604 $1.11 Million
Q4 2018

Feb 01, 2019

BUY
$36.99 - $59.11 $10,616 - $16,964
287 Added 3.8%
7,849 $361,000
Q3 2018

Oct 25, 2018

BUY
$40.74 - $51.41 $91,094 - $114,952
2,236 Added 41.98%
7,562 $336,000
Q2 2018

Jul 20, 2018

SELL
$36.2 - $76.4 $365,982 - $772,404
-10,110 Reduced 65.5%
5,326 $209,000
Q1 2018

Apr 18, 2018

BUY
$65.94 - $80.76 $702,920 - $860,901
10,660 Added 223.2%
15,436 $1.12 Million
Q4 2017

Jan 17, 2018

BUY
$43.47 - $67.43 $207,612 - $322,045
4,776
4,776 $314,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $171M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.